Dermata Therapeutics Inc DRMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
-
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
-
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
-
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
-
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
Trading Information
- Previous Close Price
- $0.86
- Day Range
- $0.83–0.93
- 52-Week Range
- $0.60–4.66
- Bid/Ask
- $0.85 / $0.91
- Shares Outstanding
- 4.96M
- Market Cap
- $4.31M
- Volume/Avg
- 2,064 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.dermatarx.com
Valuation
|
Metric
|
DRMA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
DRMA
Financial Strength
|
Metric
|
DRMA
|
|---|---|
Quick Ratio | 2.41 |
Current Ratio | 2.81 |
Interest Coverage | — |
Quick Ratio
DRMA
Profitability
|
Metric
|
DRMA
|
|---|---|
Return on Assets (Normalized) | −126.94% |
Return on Equity (Normalized) | −159.86% |
Return on Invested Capital (Normalized) | −164.38% |
Return on Assets
DRMA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<GM<@< | LOCK|ZkKs | $130B | |||
| Moderna Inc
MRNA
| LOCK|Q$?WY@ | LOCK|L^> | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|BC#LL^ | LOCK|D%Cb | $83B | |||
| argenx SE ADR
ARGX
| LOCK|pB$&x< | LOCK|%?^ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|x&qKq?# | LOCK|@G | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kJ&bcRw | LOCK|^cQ< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|zVP<xjw! | LOCK|fVF@ | $28B | |||
| Incyte Corp
INCY
| LOCK|R^Lhh! | LOCK|<k | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|m@Q$K% | LOCK|$#% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|C!Xf^? | LOCK|gW^ | $14B |
United States